Skip to main content
CLRB logo

CLRB

Cellectar Biosciences, Inc.
$2.81 -0.02 (-0.71%) At close · Jul 2
Market Cap
$22.46M
Shares
7,991,812

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.81 Open$2.85 Day$2.77–3.02 52W$2.20–6.52 Avg vol 30d153K Short int57K · 0.7% float · 1.0d Short vol75% Last earningsMay 14, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 14
Equibles Rating blended score · not investment advice
Overall
Buy
Technical · trend & momentum Neutral
50 / 200-day cross no cross
Price vs 200-day avg −16% below
+ Price vs 50-day avg +0% above
RSI (14) 56 · neutral
+ MACD trend positive
52-week position 14% · near low
Sentiment · smart money Bullish
Trend (MA cross) 50d $3 › 200d $3 — 200d above 50d
Institutional flow -5% holders QoQ · +4 funds added
+ Insider flow Net +$50.0K over 90 days · 0% sells
+ Short interest 0.72% of float · ▼ -77.8% MoM · 1.0 days cover
Volume signal Volume near normal
Institution breadth 19 holders — near 1-yr low, contrarian setup
Fundamentals Strong
+ EPS growth +80% Y/Y
Free cash flow $-23.1M
+ Balance sheet net cash $12.9M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next
Next earnings call
Aug 14, 2026 Est · unconfirmed · in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 14, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 2 · 2
      50 / 200-day cross
      no cross Neutral
      Price vs 200-day avg
      −16% below Bearish
      Price vs 50-day avg
      +0% above Bullish
      RSI (14)
      56 · neutral Neutral
      MACD trend
      positive Bullish
      52-week position
      14% · near low Bearish
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $3 › 200d $3 — 200d above 50d
      Institutional flow Distributing
      -5% holders QoQ · +4 funds added
      Insider flow Accumulating
      Net +$50.0K over 90 days · 0% sells
      Short interest Falling
      0.72% of float · ▼ -77.8% MoM · 1.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      19 holders — near 1-yr low, contrarian setup
      Price context
      position in its 52-week range
      52-wk low $2 Now $3 · 14% 52-wk high $7
      vs 200-day avg -16% vs 50-day avg +0%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Disease control rate (DCR) 98.2% Phase 2b CLOVER WaM study
      Major response rate (MRR) 61.8% Phase 2b CLOVER WaM study
      Median duration of response (DoR) 17.8 Phase 2b CLOVER WaM study
      Median progression-free survival (PFS) 13.5 Phase 2b CLOVER WaM study
      Overall response rate (ORR) 83.6% Phase 2b CLOVER WaM study
      Very good partial response/complete response rate (VGPR/CR) 14.5% Phase 2b CLOVER WaM study

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CLRB
      Cellectar Biosciences, Inc.
      this stock
      $22.46M -4.7% 0.7%
      AKTX
      Akari Therapeutics Plc
      $953.21B -9.9% 0.0%
      ONC
      BeOne Medicines Ltd.
      $470.30B -2.0% +22179.2% 957.1 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $134.02B +16.5% +46.2% 31.3 1.8%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $69.80B -15.1% +20.8% 16.3 3.2%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      19
      % held
      3.9%
      Net QoQ
      -36.1K sh
      Top holder
      Bleichroeder LP
      Held Float
      View
      Held by Funds
      Fund positions
      7
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      57.4K
      Days to cover
      1.0d
      Change
      -200.8K sh
      View
      Short Volume
      Short vol %
      75%
      As of
      Jul 2, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2.3K
      Value
      $5.4K
      As of
      Jun 10, 2026
      View
      Off-Exchange
      Off-exchange %
      48.4%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$50.0K
      Buyers / Sellers
      2 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Net income (FY)
      $-21.8M
      EPS diluted
      $-8.35
      View
      Filings
      SEC Filings
      Latest
      DEF 14A
      Filed
      May 28, 2026
      This year
      8
      View
      Exempt Offerings
      Offering
      $24.5M
      Filed
      Sep 22, 2023
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Jul 7, 2026
      Last call
      May 14, 2026
      View
      Investor Relations
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      CLRB +13.8% +8.1% -15.1% +1.1% -4.8%
      SPY +1.4% -1.3% +8.0% -0.3% +9.2%
      vs SPY +12.3% +9.3% -23.1% +1.4% -14.0%
      Key facts CIK 1279704 CUSIP 15117F880 Visit website Investor relations